LYMPHOMA & MYELOMA CONNECT

LYMPHOMA & MYELOMA CONNECT is an international group of experts in the field of hematological malignancies and is an initiative of COR2ED. The group discusses the latest scientific and clinical insights, identifies educational needs, and develops educational programmes to support healthcare professionals globally to provide the best possible care to their patients.

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Karyopharm Therapeutics and Menarini Stemline Oncology.

Meet the LYMPHOMA & MYELOMA CONNECT experts

What’s new from LYMPHOMA & MYELOMA CONNECT

Load more Explore all our programmes

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

What’s new from LYMPHOMA & MYELOMA CONNECT

Early relapsed/refractory multiple myeloma (RRMM): best practices in management

Experts

Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Experts

Episode

6

of 6

Listen to Expert Insights on Late-Breaking Data from ASCO 2023

Experts

Update From ASH 2022

Experts

Update from ASCO 2022 – Myeloma

Experts

Episode

3

of 3

Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Experts